摘要
目的：①通过免疫组化S-P法和RT-qPCR方法检测Lumican在人大肠癌中的表达；②研究Lumican与上皮粘附分子E-cadherin、基质降解酶MMP-7表达的相关性，初步探讨Lumican在大肠癌中的表达、临床意义及其与大肠癌发生、发展及浸润、转移的关系。
方法：收集64例大肠癌组织及其对应的37例癌旁组织、远离癌的27例正常大肠组织蜡块。①应用免疫组化S-P法检测上述同一组织内Lumican、E-cadherin及MMP-7蛋白表达；②分别提取27例新鲜大肠癌组织及远离肿瘤的正常大肠组织RNA，应用荧光定量聚合酶链反应（RT-qPCR)技术检测Lumican mRNA相对表达量；③结合Lumican表达的临床意义，就其与相应同一组织内E-cadherin、MMP-7表达相关性行统计学分析。统计学分析采用SPSS19.0软件。
结果：①免疫组化显示Lumican蛋白阳性染色定位于胞膜，癌细胞过表达，癌旁成纤维细胞亦有表达，正常大肠上皮细胞不表达。64例大肠癌、37例癌旁组织Lumican阳性表达率分别为73.44%（47/64）、67.57%（25/37），差异无统计学意义（P>0.05）。27例正常大肠组织无一例表达Lumican，表达率为0%（0/27），显著低于癌组织、癌旁组织表达，差异有统计学意义（P<0.001）。大肠癌组织Lumican蛋白表达与患者性别、年龄、发病部位无关，而与病理分化程度、Dukes分期、淋巴结是否转移相关；分化越差，Dukes分期越晚，伴淋巴结转移，Lumican表达越高，差异均有统计学意义（P<0.001）。②E-cadherin阳性染色定位在上皮细胞-细胞接触侧细胞膜上；MMP-7主要表达在胞质，部分胞膜染色，间质不染或浅染。大肠癌组织E-cadherin、MMP-7阳性表达率分别为34.38%（22/64）、68.75（44/64），两者表达呈负相关（r=－0.648），有统计学意义（P<0.01）。③Lumican mRNA在大肠癌组织中表达高于远离肿瘤的正常组织表达（P<0.001）。同一大肠癌组织免疫组化检测Lumican蛋白量与RT-qPCR检测Lumican mRNA相对表达量呈正相关（r=0.123），但无统计学意义（P>0.05）。④Lumican表达与E-cadherin表达呈负相关（r=－0.570），Lumican与MMP-7表达呈正相关（r=0.701），均有统计学意义（P<0.01）。
结论：①大肠癌组织中Lumican mRNA和蛋白均较正常大肠组织表达升高，大肠癌组织Lumican mRNA升高引起翻译生成的Lumican蛋白表达增多。Lumican蛋白表达与大肠癌组织学分级、Dukes分期及淋巴结是否转移有关。②大肠癌中E-cadherin和MMP-7表达与组织学分级、Dukes分期及淋巴结是否转移密切相关，E-cadherin低表达与MMP-7高表达在大肠癌的侵袭和转移过程中可能有一定的协同作用。③Lumican蛋白表达与E-cadherin呈负相关，而与MMP-7呈正相关。联合检测Lumican、E-cadherin及MMP-7可作为评价大肠癌恶性生物学行为指标。
Objective: To quantify the expression of Lumican in the human colorectal carcinomatissue by immunohistochemistry and RT-qPCR, and to study its correlation with theexpression of E-cadherin and MMP-7, in order to investigate the expression of Lumicanand its significance with the progression of colorectal carcinoma.
Methods: Protein levels of Lumican, E-cadherin and MMP-7in paraffin sections of64cases of colorectal carcinoma,37cases of adjacent mucosa and27cases of distantnormal mucosa were determined by immunohistochemical Streptavidin-perxiodasetechnique, mRNA levels of Lumican of27cases of colorectal carcinoma and distantnormal mucosa was quantified by RT-qPCR. Additionally, clinical parameters includinggender and age of these patients and the site, grade were recorded, the protein levels ofE-cadherin and MMP-7in the same colorectal carcinoma tissue were determined byimmunohistochemistry. Finally, the relationship between the expression of Lumican ofE-cadherin, MMP-7in protein levels in the same patients with colon carcinoma wereanalyzed by SPSS.
Results:①.Immunohistochemical results:Based on its immunoreactivity, theLumican protein was found to be localized in the cell membrane of colorectal cancer cellsand fibroblasts of stromal tissues adjacent to cancer cells, but not in colorectal carcinomaand adjacent normal mucosa were73.44%and67.57%, which were significantly higherthan that in distant normal mucosa of0%(p<0.001). The expression of Lumican incolorectal carcinoma were significantly correlated with the tumor differentiation, theDukes stage and lymph node metastasis, but there is no relationship between the Lumicanexpression and age, sex, attacking location and the size of tumor.②.The expression ofLumican mRNA in colorectal carcinoma were higher than that in distant normal mucosa.The expression of Lumican protein was positively correlated with Lumican mRNA in the same colorectal carcinoma, but this was not statistically significant (p>0.05).③.Based onits immunoreactivity, the E-cadherin protein was found to be localized in the cellmembrane of colorectal cancer cells, MMP-7protein was expressed in both of cellmembrane and cytoplasma, but weekly in the stromal tissues. The positive rate ofE-cadherin and MMP-7protein expression in colorectal carcinoma wererespectively:34.38%%and68.75%. There was a negative association between E-cadherinprotein and MMP-7（r=－0.648, P<0.01）.④.There was a negative association betweenLumican protein and E-cadherin（r=-0.570, P<0.01）, whereas a positive associationbetween Lumican and MMP-7（r=0.701, P<0.01）.
Conclusion: The Lumican proteins and mRNA in colorectal carcinoma weresignificantly higher than those in distant normal mucosa. The expression of Lumican incolorectal carcinoma were significantly correlated with the tumor differentiation, theDukes stage and lymph node metastasis. Lower E-cadherin and higher MMP-7expressionmay be positively correlated with the development of the relative later stages of colorectalcarcinoma. The expression of Lumican protein and E-cadherin, MMP-7was correlated incolorectal carcinoma. The above three interacted with each other during the progression ofcolorectal carcinoma.
引文
[1]张思维,雷正龙,李光琳,等.中国肿瘤登记地区2006年肿瘤发病和死亡资料分析[J].中国肿瘤,2010,19(6):356-365.
[2] Hayashi N, Ito I, Yanagisawa A, etal. Genetic diagnosis of lymph-node metastasis incolorectal cancer[J]. Lancet,1995,345(8960):1257-1259.
[3] Zenya Naito. Role of the samll leucine-rich proteoglycan(SLRP) family in pathologicallesions and cancer cell growth[J]. Nippon Med Sch,2005,43(11):137-145.
[4] Yeo TK, Brown L, Dvorak HF. Alterations in proteoglycan synthesis common tohealing wounds and tumors[J]. J Pathol,2000,192(3):313-320.
[5] Chakravarti S, Zhang G, Chervoneva I, et al. Collagen fibril assembly during postnataldevelopment and dysfunctions regulation in the lumican-deficient murine corneal[J].Dev Dyn,2006,235(9):2493-2506.
[6] Tran KT, Lamb P, Deng JS. Matrikines and matricryptins:Implication for cutaneouscancers and skin repair[J]. Dermatol Sci,2005,40(1):11-20.
[7] Legue E, Snell L, Dotzlaw H, et al. Expression of lumican in human breastcarcinoma[J]. Cancer Res,1998,58(7):1348-1352.
[8] Zenya Naito, Toshiyuki Ishiwata, Gulnar Kurban, et al. Expression and accumlation oflumican protein in uterine cervical cancer cells at the periphery of cancer nests[J].International Journal of Oncology,2002,20(5):943-948.
[9] Ping Lu Y, Ishiwata T, Asano G. Lumican expression in alpha cells of islets in pancreasand pancreatic cancer cells[J]. J Pathol,2002,196(3):324-330.
[10] Toshiyuki Ishiwata, Kazumitsu Cho, Kiyoko Kawahara, et al. Role of lumican incancer cells and adjacent stromal tissues in human pancreatic cancer[J]. OncologyReports,2007,18(3):537-543.
[11]罗海蓉,刘连新,姜洪池.抑癌基因Lumican在胃癌中的表达及其临床意义.中国普外基础与临床杂志,2007,14(5):551-553.
[12] Yue Ping Lu, Toshiyuki Ishiwata, Kiyoko Kawahara, et al. Expression of lumican inhuman colotectal cancer cells [J]. Pathology International,2002,52(8):519-526.
[13]宋洪江,佟丹丹,金银姬,等.应用组织芯片技术研究结直肠癌中Lumican的表达及意义[J].中国普外基础与临床杂志,2007,14:(10)551-553.
[14] Shiozaki H, Oka H, Inone M, et al. E-cadherin imediated adhesion system in cancercells[J]. Cancer,1996,77(8):1605.
[15] Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulartor[J].Science,1991,251:1451-1455.
[16] Kanazawa N, Oda T, Gunji N, et al. E-cadherin expression in the primary tumors andmetastatic lymph nodes of poorly differentiated types of rectal cancer[J]. Surg Today,2002,32(2):123-128.
[17]苏剑敏,周逸平,徐薇苓,等. E-钙粘蛋白在四种肿瘤中表达的比较[J].中华肿瘤杂志,2000,22(3):212-213.
[18] Kim HS, Hong EK, Park SY, et al. Expression of beta-catenin and E-cadherin in theadenoma-carcinoma sequence of the stomach[J]. Anticancer Res,2003,23(3C):2863-2868.
[19] Cai T, Piazzini M, Nesi G, et al. E-cadherin mRNA expression analysis in evaluatingthe natural history of urothelial bladder cell carcinoma:results from a long-termfollow-up study[J], Oncol Rep,2007,17(4):925-930.
[20] Wu H, Liang YL, Li Z, et al. Positive expression of E-cadherin suppresses celladhesion to fibronectin via reduction of alpha5betal integrin in human breastcarcinoma cells[J]. Cancer Res Clin Oncol,2006,132(12):795-803.
[21] Tamura G, Yin J, Wang S, et al. E-cadherin gene promoter hypermethylation inprimary human gastric carcinomas[J]. J Natl Cancer Inst,2000,92(7):569-573.
[22] Makarla PB, Saboorian MH, Ashfaq R, et al. Promoter hypermethylation profile ofovarian epithelial neoplasms[J]. Clin Cancer Res,2005,11(15):5365-5369.
[23] Caldeira JR, Prando EC, Quevedo FC, et al. CDH1promoter hypermethylation andE-cadherin protein expression in infiltraing breast cancer[J]. BMC Cancer,2006,6(1):48.
[24] Li Q, Mattingly RR. Restoration of E-cadherin in cell-cell junction requires bothexpression of E-cadherin and suppression of ERK MAP kinase activation inRas-transformed breast epithelial cells[J]. Neoplasia,2008,10(12):1444-1458.
[25] Selga E, Morales C, Noe V, etal. Role of caveolin1, E-cadherin, Enolase2andPKCalpha on resistance to methotrexate in human HT29colon cancer cells[J]. BMCMed Genomics,2008,1(1):1-17.
[26] Yoshida S, Hinoda Y. Expression of matrix metalloproteinase2and7in tumor cellscorrelates with the world health organization classification subtype and clinical stageof thymic epithelial tumors[J]. Hum Pathol,2003,34(12):1253-1258.
[27] Imai K, Yokohama Y, Nakanishi T, et al. Matrix metalloproteinase7(matrilysin) fromhuman rectal carcinoma cells. Activation of the precursor, interaction with othermetalloproteinases and enzymatic properties[J]. J Biol Chem,1995,270(12):6691-6697.
[28]邢亚恒,张庆宪,李春燕. KISS-1和MMP-7在非小细胞肺癌组织中的表达及意义[J].山东医药,2008,48(29):32-33.
[29] Maurel J, Nadal C, Garcia-Albeniz X, et al. Serum matrix metalloproteinase7levelsidentifies poor prognosis anvanced colorectal cancer patients[J]. Int Cancer,2007,121(5):1066-1071.
[30] Itoh F, Yamaoto H, Hinoda Y, et al. Enhanced secretion and activation of matrilysinduring malignant conversion of human colorectal epithelium and its relationship withinvasive potential of colon cancer cells[J]. Cancer,1996,77(8):1712-1721.
[31] Izumiyama Y, Higashino F, etal. EAF expression is closely correlated with maligantphenotupe of MMP gene promotes[J]. Oncology,2005,13(4):715-720.
[32] Noe V, Fingleton B, Jacobs KC, etal. Release of an invasion promoter E-cadherinfragment by matrilysin and stromelysin-1[J]. Cell Sci,2001,114(Pt1):111-118.
[33] Yingyi Li, Takanori Aoko, Yuya Mori, et al. Cleavage of lumican by membrane-typematrix metalloproteinase-1abrogates. This proteoglycan-mediated suppression oftumor cell colony[J]. Cancer Res,2004,10(64):7058-7064.
[34]王佳,王晶. SLRP与恶性肿瘤.实用肿瘤学杂志,2009,23(3):293-296.
[35] Moseley R, Stewart JE, Stephens P, et al. Extracellular matrix metabolites as potentialbiomarkers of disease activity in wound fluid:lessons learned from otherinflammatory disease[J]. Br Dermatol,2004,159(3):401-413.
[36] Hardingham TE, Fosang AJ. Proteoglycans:many forms and many functions[J].FASEB J,1992,6(3):861-870.
[37] Troup S, Njue C, Kliewer EV, et al. Reduced expression of the small leucine-richproteoglycans, lumican, and decorin is associated with poor outcome in node-negativeinvasive breast cancer[J]. Clin Cancer Res,2003,9(1):207-214.
[38] Yomo Matsuda, Tetsushi Yamamoto, Mitsuhiro Kudo, et al. Expression of lumican inlung adenocarcinoma and squamous cell carcinoma[J]. International Journal ofOncology,2008,33(6):1177-1185.
[39] Nikitovic D, Berdiaki A, Zafiropoulos, et al. Lumican expression is positivelycorrelated with the differentiation and negatively with the growth of humanosteosarcoma cells[J].2008,275(2):350-361.
[40] Brezillon S, Venteo L, Ramont L,et al. Expression of lumican, a small proteoglycanwith antitumor activity, in human malignant melanoma[J]. Clin Exp Dermatol,2007,32(4):405-416.
[41] Shinji S, Tajiri T, Ishiwata T, et al. Different expression levels of lumican in humancarcinoid tumor and neuroendocrine cell carcinoma[J]. Int J Oncol,2005,26(4):873-880.
[42] Zenya Naito, Toshiyuki Ishiwata, Gulnar Kurban, et al. Expression and accumlation oflumican protein in uterine cervical cancer cells at the periphery of cancer nests[J].International Journal of Oncology,2002,20(5):943-948.
[43] Michelacci YM. Collagens and proteoglycans of the corneal extracellular matrix[J].Braz J Med Biol Res,2003,36(8):1037-1046.
[44] Yeo TK, Brown L, Dvorak HF. Alterations in proteoglycan synthesis common tohealing wounds and tumors[J]. J Pathol,2000,192(3):313-320.
[45] Tetsushi Yamamoto, Yoko Matsuda, Kiyoko Kawahara, et al. Secreted70kda lumicanstimulates growth and inhabits invasion of human pancreatic cancer[J]. Cancer Letters,2012,320(1):31-39.
[46] Tomoko Seya, Noritake Tanaka, Seiichi Shinji, et al. Lumican expression in advancedcolorectal cancer with nodal metastasis correlates with poor prognosis[J]. OncologyReports,2006,16(6):1225-1230.
[47] Saika S, Miyamoto T, Tanaka S, et al. Response of lens epithelial cells to injury: roleof Lumican in epithelial-mesenchymal transition[J]. Invest Ophtalmol Vis Sci,2003,44(5):2094.
[48] Nikitovic D, Berdiaki A, Zafiropoulos A, et al. Lumican expression is positivelycorrelated with the differentiation and negatively with the growth of humanosteosarcoma cells[J]. FEBS J,2008,275(2):350-361.
[49] Imai K, Hiramatsu A, Fukushima D, et al. Degradation of the decorin by matrixmetalloproteinsases:identification of the cleavage sites, kinetic analyses andtransorming growth factor-beta1release[J]. Biochem J,1997,322:809-14.
[50]陈开荣,李万成,黄旭晴.转化生长因子β/Smad途径在血管生成和促纤维化中的作用及切换[J].国际呼吸杂志,2009,2(29):244-247.
[1] Gover J, Chen XN, Korenberg JR, et al. The human lumican gene [J]. Biol Chem,1995,270(37):21942-21949.
[2] Svensson L, Narlid I, Oldberg A. Fibromodulin and lumican bind to the same region oncollagen type Ⅰ fibrils [J]. FEBS Lett,2000,470(2):178-182.
[3] Kresse H, Schonherr E. Proteoglycan of the extracellular matrix and growth control[J].Cell Physiol,2001,189(3):266-274.
[4]石宏,王洁.蛋白多糖与涎腺肿瘤,现代口腔医学杂志,2010,24(6):460-463.
[5]王佳,王晶. SLRP与恶性肿瘤.实用肿瘤学杂志,2009,23(3):293-296.
[6] Moseley R, Stewart JE, Stephens P, et al. Extracellular matrix metabolites as potentialbiomarkers of disease activity in wound fluid:lessons learned from otherinflammatory disease[J]. Br Dermatol,2004,159(3):401-413.
[7] Hardingham TE, Fosang AJ. Proteoglycans:many forms and many functions[J]. FASEBJ,1992,6(3):861-870.
[8] Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities[J].Cell,1991,64(5）：867-869.
[9] Yeo TK, Brown L, Dvorak HF. Alterations in proteoglycan synthesis common tohealing wounds and tumors[J]. Pathol,2000,192(3):313-320.
[10] Rosetta Merline, Roland M.Schaefer, Liliana Schaefer. The matricellular functions ofsmall leucine-rich proteoglycans (SLRPs)[J]. Cell Commun,2009,3(3-4):323-335.
[11] Zenya Naito. Role of the samll leucine-rich proteoglycan(SLRP) family inpathological lesions and cancer cell growth[J]. Nippon Med Sch,2005,43(11):137-145.
[12] Fullwood NJ, Davies Y, Nieduszynski IA, et al. Cell surface-associated keratan sulfateon normal and migrating corneal endothlium[J]. Invest Ophalmol Vis Sci,1996,37(7):1256-1270.
[13] Grover J, Chen XN, Korenberg JR, et al. The human lumican gene. Organization,Chromosomal location, and expression in artilage[J]. J Boil Chem,1995,270(37):21942-21949.
[14] Liu CY, Shairaishi A, Kao CW, et al. The cloing of nouse keratocan cDNA andgenomic DNA and the characterization of its expression during eye development[J]. JBiol Chem,1998,273(35):22584-22588.
[15] Chakravarti S, Stallings RL, SundaRaj N, et al. Primary structure of humanlumican(keratan sulfate proteoglycan) and localization of the gene(LUM) tochromosome12q21.3-q22[J]. Genomics,1995,27(3):481-488.
[16] Sommarin Y, Wendel M, Shen Z, et al. Osteoadherin, a cell-binding keratin sulafateproteoglycan in bone,belongs to the family of leucine-rich repeat proteins of theextracellular matrix[J]. J Biol Chem,1998,273(27):16723-16729.
[17] Quantock AJ, Meek KM, Chakravarti S. An X-ray diffraction investigation of cornealstructure in lumican-difficient mice[J]. Invest Ophthalmol Vis Sci,2001,42(8):1750-1756.
[18] Cornuet PK, Blochberger TC, Hassell JR. Molecular polymorphism of lumican duringcorneal development[J]. Invest Ophthalmol Vis Sci,1994,35(3):870-877.
[19] Michelacci YM. Collagens and proteoglycans of the corneal extracellular matrix[J].Braz J Med Biol Res,2003,36(8):1037-1046.
[20] Young Seomun, Choun-Ki Joo. Lumican induces human corneal epithelial cellmigration and integrin expression via ERK1/2signaling[J]. Biochemical andBiophysical Research Communications,2008,372(1):221-225.
[21] Sztrolovics R, Alini M, Mort JS, et al. Age-related changes in fibromodulin andlumican in human intervertebral discs[J]. Spine,1999,24(17):1765-1771.
[22] Saika S, Shiraishi A, Liu CY, et al. Role of lumican in the corneal epithelium duringwound healing[J]. J Biol Chem,2000,275(4):2607-2612.
[23] Baba H, Ishiwata T, Takashi E, et al. Expression and localization of lumican in theischemic and reperfused rat heart[J]. Jpn Circ J,2001,65(5):445-450.
[24] Qin H, Ishiwata T, Asano G. Effects of the extracellular matrix on lumican expressionin rat smooth muscle cells in vitro[J]. J Pathol,2001,195(5):604-608.
[25] Ping Lu Y, Ishiwata T, Asano G. Lumican expression in alpha cells of islets inpancreas and pancreatic cancer cells[J]. J Pathol,2002,196(3):324-330.
[26] Chakravarti S, Zhang G, Chervoneva I, et al. Collagen fibril assembly during postnataldevelopment and dysfunctions regulation in the lumican-deficient murine corneal[J].Dev Dyn,2006,235(9):2493-2506.
[27] Tran KT, Lamb P, Deng JS. Matrikines and matricryptins:Implication for cutaneouscancers and skin repair[J]. Dermatol Sci,2005,40(1):11-20.
[28] Chikama TI, Liu CY, Kao WW. Lumican has a critical role in modulatinginflammatory responses during corneal wound healing[J]. Invest Ophthalm Vis Sci,2004,45(9):1166-1173.
[29] Legue E, Snell L, Dotzlaw H, et al. Expression of lumican in human breastcarcinoma[J]. Cancer Res,1998,58(7):1348-1352.
[30] Linda E Kelemen, Fergus J Couch, Shahana Ahmed, et al. Genetic variation instromal proteins decorin and lumican with breast cancer:investigations in twocase-control studies[J]. Breast Cancer Research,2008,10(6):1-11.
[31] Troup S, Njue C, Kliewer EV, et al. Reduced expression of the small leucine-richproteoglycans, lumican, and decorin is associated with poor outcome in node-negativeinvasive breast cancer[J]. Clin Cancer Res,2003,9(1):207-214.
[32] Leygue E, Snell L, Dotzlaw H, et al. Lumican and decorin are differentially expressedin human breast carcinoma[J]. Pathol,2000,192(3):313-320.
[33] Yamano Y, Uzawa K, Saito K, et al. Identification of cisplatin-resistance related genesin head and neck squamous cell carcinoma[J]. Int Cancer,2010,126(2):437-449.
[34] Marisa Dolhnikoff, Jean Morin, Peter J, etal. Expression of lumican in human lungs[J].Am J Respir Cell Mol Biol,1998,19(4):582-587.
[35] Yomo Matsuda, Tetsushi Yamamoto, Mitsuhiro Kudo, et al. Expression of lumican inlung adenocarcinoma and squamous cell carcinoma[J]. International Journal ofOncology,2008,33(6):1177-1185.
[36] Yue Ping Lu, Toshiyuki Ishiwata, Kiyoko Kawahara, et al. Expression of lumican inhuman colotectal cancer cells [J]. Pathology International,2002,52(8):519-526.
[37] Tomoko Seya, Noritake Tanaka, Seiichi Shinji, et al. Lumican expression in advancedcolorectal cancer with nodal metastasis correlates with poor prognosis[J]. OncologyReports,2006,16(6):1225-1230.
[38]宋洪江,佟丹丹,金银姬,等.应用组织芯片技术研究结直肠癌中Lumican的表达及意义[J].中国肿瘤杂志,2007,10:833-836.
[39] Watanabe T, Komuro Y, Kiyomatsu T. Prediction of sensitivity rectal cancer cells inresponse to preoperative radiotherapy by DNA microarray analysis of gene expressionprofiles[J]. Cancer Res,2006,66(7):3370-3374.
[40] Toshiyuki Ishiwata, Kazumitsu Cho, Kiyoko Kawahara, et al. Role of lumican incancer cells and adjacent stromal tissues in human pancreatic cancer[J]. OncologyReports,2007,18(3):537-543.
[41] Zenya Naito, Toshiyuki Ishiwata, Yue Ping Lu, et al. Transient and ectopic expressionof lumican by aninar cells in L-Arginine-induced acute pancreatitis[J]. Experimentaland Molecular Pathology,2003,74(1),33-39.
[42] Tetsushi Yamamoto, Yoko Matsuda, Kiyoko Kawahara, et al. Secreted70kda lumicanstimulates growth and inhabits invasion of human pancreatic cancer[J]. Cancer Letters,2012,320(1):31-39.
[43] Manoj Kumar Kashyap, Arivusudar Marimuthu, Suraj Peri, et al. Overexpression ofperiostin and lumican in esophageal squamous cell carcinoma[J]. Cancers,2010,2(1):133-142.
[44]罗海蓉,刘连新,姜洪池.抑癌基因Lumican在胃癌中的表达及其临床意义.中国普外基础与临床杂志,2007,14(5):551-553.
[45] Zenya Naito, Toshiyuki Ishiwata, Gulnar Kurban, et al. Expression and accumlation oflumican protein in uterine cervical cancer cells at the periphery of cancer nests[J].International Journal of Oncology,2002,20(5):943-948.
[46] Nikitovic D, Berdiaki A, Zafiropoulos, et al. Lumican expression is positivelycorrelated with the differentiation and negatively with the growth of humanosteosarcoma cells[J].2008,275(2):350-361.
[47] Brezillon S, Venteo L, Ramont L,et al. Expression of lumican, a small proteoglycanwith antitumor activity, in human malignant melanoma. Clin Exp Dermatol,2007,32(4):405-416.
[48] Sifaki M, Assouti M, Nikitovic D, et al. Lumican,a small leucine-rich proteoglycansubstituted with keratan sulfate chains is expressed and secreted by human melanomacells and not normal melanocytes[J]. Iubmb Life,2006,58(10):606-610.
[49] Stephane Brezillon, Agata Radwanska, Cedric Zeltz, et al. Lumican core proteininhibits melanoma cell migration via alterations of focal adhesion complexes[J].Cancer Letters,2009,283(1):92-100.
[50] Shinji S, Tajiri T, Ishiwata T, et al. Different expression levels of lumican in humancarcinoid tumor and neuroendocrine cell carcinoma[J]. Int J Oncol,2005,26(4):873-880.
[51] Yeo TK, Brown L, Dvorak HF. Alterations in proteoglycan synthesis common tohealing wounds and tumors[J]. J Pathol,2000,192(3):313-320.
[52]陈开荣,李万成,黄旭晴.转化生长因子β/Smad途径在血管生成和促纤维化中的作用及切换[J].国际呼吸杂志,2009,2(29):244-247.
[53] Naito Z. The role of the small leucine-rich proteoglycan(SLRP) family in pathologicallesions and cancer cell growth[J]. Nippon Med Sch,2005,72(3):137-145.
[54] Kao WW. Ocular surface tissue morphogenesis in normal and disease states revealedby genetically modified mice[J]. Cornea,2006,25:S7-S19.
[55] James L. Funderburgh, Martha L. etal. Proteoglycan expression during transforminggrowth factor β-induced keratocyte-myofibroblast transdifferentiation[J]. Biol Chem,2001,276(47):44173-44178.
[56] Vij N, Roberts L, Joyce S, et al. Lumican supresses cell proliferation and aidsFas-Fasligand mediated apoptosis:implications in the cornea[J]. Exp Eye Res,2004,78(5):957-971.
[57] Zeltz C, Brezillon S, Kapyla J, et al. Lumican inhibits cell migration through alpha2beta1integrin[J]. Exp Cell Res,2010,316(17)2922.
[58] Funderburgh JL, Mitschler RR, Funderburgh ML, et al. Macrophage receptors forlumican. A corneal keratan sulfate proteoglycan[J]. Invest Opthalmol VIS Sci,1997,38(6):1159-1167.
[59] Han Juan Shao, Seakwoo Lee, Sherri Gae-Scott, et al. Extracellular matrix lumicanpromotes bacterial phagocytosis and Lum-/-mice show increased pseudomonasaeruginosa lung infection severity[J].2012,287(43):35860-35872.
[60] Naohisa Yoshioka, Hirokazu Inoue, Kazuyoshi Nakanishi, et al. Isolation oftransformation suppressor genes by cDNA subtraction:Lumican suppressestransformtion induced by v-src and v-k-ras[J]. Journal of Virology,2000,74(2):1008-1013.
